Image

PMA-FERTITHEQUE Biocollection

Recruiting
18 - 43 years of age
Female
Phase N/A

Powered by AI

Overview

Creation of a patient library in Medically Assisted Procreation to allow the implementation of further research with the following objectives:

  • To identify new relevant biomarkers in patients who will carry a pregnancy to term
  • To better specify or identify new infertility risk factors
  • To identify new relevant biomarkers in patients with reduced ovarian reserve

Four consultations are planned with biological et clinical collection.

Description

  • A first initial consultation for prescription of the infertility assessment,
    • a consultation 2 summarizing the examinations and delivery of prescriptions
    • a blood sample: basal hormonal assessment with AMH (Anti-Mullerian Hormone),
    • a urine sample to look for an infection with Chlamydia Trachomatis, which is one of the bacteria responsible for gynecological infections compromising ART.
    • an HPV (Human Papillomavirus) test on vaginal swab
    • a consultation 3 corresponding to the start of a treatment cycle for IVF with oocyte retrieval at the end of this treatment cycle.
    • A consultation lasting 4 to 4-6 weeks to take stock of the success or failure of the ART.
    • A pregnancy follow-up consultation if successful, for a pelvic ultrasound, then monthly pregnancy follow-up (one consultation per month).
    • As part of the usual ART monitoring, clinical and paraclinical data are collected using the MEDIFIRST software.
    • During the inclusion visit, questionnaire => will be completed over an additional time to the consultation if inclusion is desired, inclusion time provided by one of the doctors participating in the study.

For the FERTITHEQUE, will be collected:

  • clinical characteristics collected at each consultation as part of the usual follow-up.
  • biological characteristics measured as part of the usual follow-up.
  • During consultation 2, during a blood test carried out as part of your usual care, additional tubes will be taken (4 to 5 tubes of 10mL) to carry out the banking of DNA (support of genetic information), plasma (plasma library), serum (serotheque).
  • During consultation 2, a swab will also be taken from the vaginal microbiota.
  • During consultation 3, a conservation of the follicular fluid (puncture fluid) will be carried out.
  • During consultation 4, a plasma library will be performed again, whether there is pregnancy or not, as well as a new swab sample for the vaginal microbiota.

Then, as described above, patients are after inclusion as part of the usual IVF follow-up reviewed at 1 month for oocyte retrieval then at 2 months for the follow-up visit allowing observation of success or failure of the treatment cycle.

  • If pregnancy is achieved, patients are seen monthly as part of their usual follow-up until delivery.
  • If a pregnancy is not achieved, follow-up stops.
  • Whether or not a pregnancy is obtained, during the visit at 2 months (V4), a plasma library and a vaginal microbiota are again performed.

Eligibility

Inclusion Criteria:

  • Signed consent
  • Aged 18 to 43
  • Infertility for at least 12 months
  • Oriented in IVF
  • Infertility of unexplained origin or presenting a low ovarian reserve before the age of 35 (AMH<1.1ng and/or CFA<7).

Exclusion Criteria:

  • Minor patients or > 43 years old
  • Patients under guardianship, curatorship (legal protection)
  • Refusal to participate
  • Patient unable to consent

Study details

Infertility, Infertility Unexplained

NCT05599724

University Hospital, Brest

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.